Q1FY26 Quarterly Activities Report/Appendix 4C
Released
Released
Announcement PDF
1
Q1 FY26 Quarterly Activities Report
SYDNEY, Australia 27 October 2025 – Tetratherix Limited (ASX: TTX) is pleased to release its
Appendix 4C and quarterly activities report for the period ended 30 September 2025.
Key highlights for the quarter (Q1 FY26):
Tutelix: Positive results from the successful first in human insertion of the Tutelix hydrogel
spacer in Australia and progression to stage 2 of the TUTELA clinical study
• Positive data read out from the TUTELA trial - the Tutelix first in human clinical investigation
that has delivered results from multiple product insertions at the Gold Coast University
Hospital and patients’ follow up visits for the critical follow up time point of 4 weeks post
operation.
• Patients in stage 1 of the clinical study were successfully implanted with the Tutelix spacer
with no product related adverse events to date.
• The Tutelix hydrogel spacer products were successfully injected, instantly forming a hydrogel
structure at the intended site.
• During the administration process and product gelation, high visibility of prostate via trans
rectal ultrasound (TRUS) was maintained. This proposition of the technology minimises the
risk of injury related to the procedure.
• Tutelix hydrogel spacer retained its structure in all patients, and, to date, excellent product
stability has been achieved post-implantation throughout the radiotherapy delivery allowing
for consistent setup of patients and delivery of radiotherapy.
• Patient recruitment in stage 2 of the TUTELA clinical study has now been initiated in multiple
sites across Australia.
• Activation of pathways expected to commence Q1/Q2 CY26 for large pivotal trials in Australia
and the US
Dr Andrew Oar - Principal Investigator Radiation Oncologist at Gold Coast University Hospital
noted:
“The early results demonstrate very encouraging procedural safety in addition to excellent
stability of the product during prostate radiation. The team is very excited to continue
recruitment to the TUTELA trial with the aim to complete patient recruitment and product
insertion over the next 3 months. Furthermore, it gives us the confidence to commence
activation pathways for our pivotal trial in Australia and United States in CY26.”
ASX ANNOUNCEMENT
27 October 2025
2
Tetratherix is pleased to announce that its Joint Venture partner, Tutelix Pty Ltd has completed its
first Safety Review Meeting (SRM) post-completion of Stage 1 of the TUTELA clinical trial. The
Safety Review Committee (SRC) has met and discussed the clinical trial progress after a
minimum 28 day follow up for the first patients on the TUTELA trial. The SRC noted that, to date,
no procedural related adverse events have occurred. During the insertion of the Tutelix hydrogel
spacer, the prostate remained visible via TRUS allowing for simple and safe administration of the
Tutelix hydrogel spacer and minimising the risk of rectal perforation and local trauma.
Post-Tutelix hydrogel spacer insertion and during radiotherapy delivery the presence of the Tutelix
hydrogel spacer minimised the high dose received by the rectum, which is expected to reduce
radiation related side effects. Importantly, the size and the structure of Tutelix hydrogel spacer
remained unchanged during the treatment period which involved 20 sessions of radiation.
Stability of the Tutelix hydrogel spacer from computed tomography simulation to the first
treatment session and to the last treatment session was excellent, allowing for consistent setup
of patients and safe delivery of radiotherapy.
As previously planned, stage 2 of the TUTELA trial has been initiated and patient recruitment is
under way.
Bone regeneration animal FDA studies on track for Tegenix and TegenEOS
• Tegenix animal study implantation has commenced, and FDA submission timing remains on
track.
• TegenEOS animal study implementation is planned for Q2 FY26 and FDA submission timing
remains on track.
Tetratherix has been successful in securing a $3.3 million non-dilutive Australian
Government Industry Growth Program (IGP) grant.
• The project, titled ‘Synthetic polymer Production Facility to Take TetramatrixTM
Global,’ funds
a number of strategic pillars of the company’s growth including an expansion of production
capacity and key development activities.
• The $7.4m cost of the project is budgeted and aligned with the use of funds in Tetratherix’IPO
Prospectus. The project now is co-funded with $3.3 million support from the Australian
Government, which is upside to the Company’s use of funds.
• Tetratherix has provided its first quarterly report to the government with all agreed project
milestones on track. Tetratherix will continue to provide these quarterly reports against
agreed project milestones till the expected completion of the project in June 2027.
Tetratherix executes new lease agreement for Advanced Manufacturing capability.
• Tetratherix signed a lease agreement for a new facility in Alexandria, Sydney, which will house
its advanced manufacturing capability and company headquarters.
• The facility is approximately 2,800 sqm (10 times the current facility) and is a key enabler of
the Company’s manufacturing expansion strategy.
• The associated lease expenses along with capital costs are in line with the assumptions in
Tetratherix’s use of funds outlined in the Company’s prospectus.
3
Tetratherix maintains ISO quality certification for 8 years running.
• Tetratherix has completed its annual quality surveillance audit and maintained its ISO13485
certification for the eighth consecutive year.
• Every product development built on the platform has been designed and developed under the
Company’s ISO quality certification system.
• This certification governs TTX’s quality management system, production and design and
development activities, and demonstrates the Company’s ongoing commitment to high
quality standards.
Company Financial commentary
• Strong cash on hand position $24.8 million as at 30 September 2025, with zero debt
financing.
• $0.4 million cash inflows for Q1, driven by Industry Growth Program (IGP) grant, interest
income, and a prior period one off R&D tax incentive rebate adjustment.
• ($4.1) million cash outflows for Q1, is consolidated with May and June 2025 outflows in
Appendix 1 use of funds table. Key drivers are continued investment in R&D programs, capital
expenditure for the Company’s new advanced manufacturing facility, final IPO offer costs and
ongoing listing and working capital expenditure.
• ($0.8) million for establishment of a bank guarantee security deposit on the new lease for
the Company’s manufacturing upscale.
• Tetratherix is in a strong position to continue its focus on investment in Research and
Development and expansion of its advanced manufacturing capabilities with its closing
cash balance in line with prospectus assumptions.
• In accordance with ASX Listing Rule 4.7C.3, Tetratherix advises that an amount of $780k was
paid during the quarter to related parties and associates as disclosed in item 6.1 of the
Appendix 4C. These payments comprised of: $455K for executive and non-executive
directors’ salaries, superannuation, and listing incentive bonus; and $325K (including GST)
in directors’ fees and listing incentive bonus paid to entities associated with directors.
“Q1 FY26 marks a new chapter for TTX; our first full quarter as a listed company, and one defined
by tangible progress and execution. The Tutelix First in Human study represents more than a
clinical milestone; it is a significant moment where another polymer design built on our platform
technology has meet its clinical purpose — proving safety, performance, and the promise of our
tissue spacing platform. The IGP grant reinforces this direction, co-funding programs already in
motion and further validating our trajectory of disciplined growth. And with our new headquarters
and our Advanced Manufacturing facility now secured, we are building not just capacity, but the
physical foundation for the next phase of TTX — where innovation meets global scale.”
- Will Knox, CEO of Tetratherix.
4
Q2 FY26 Key Business Priorities
• Tutelix : following successful First in Human trial, Cohort 2 will progress. In addition, Tutelix
Pty Ltd will continue work on the design and implementation for the pivotal clinical trial for
FDA-510(k) clearance.
• Tegenix and TegenEOS regulatory clearance path is to progress as planned for FDA pre-
clinical studies, with expected timelines on track for product clearances in H2 FY26. These
FDA-510(k) clearances will enable the company to continue its commercialisation activities
under its bone regeneration franchise with its corporate partners.
• TetraDerm clinical trial, expected to complete the second safety committee meeting with
recruited Cohort 2 patients. Cohort 3 patients to commence in Q3 FY26, which will focus the
product performance in complex plastic and reconstructive surgeries. Achieving the primary
end points for this stage of the trial will enable the progression of the trial for the Company’s
longer-term strategy, including FDA pre-submission and confirming potential corporate
partnerships for the tissue healing franchise.
• Optelex pre-clinical validation studies have commenced; next steps involve focusing on
formulation optimisation and performance data readout.
• BioOptix joint venture capital raising activities progressing with strategic partnership
discussions.
• Fit out of Advanced manufacturing facility to continue, with the anticipated relocation of
the Company’s new headquarters, R&D laboratory, and manufacturing facility in H2 FY26.
Authorised for release by CEO and CFO.
For further information contact:
Jacob Pfeffer
General Counsel
+61 425 194 200
jacob.pfeffer@tetratherix.com
https://tetratherix.com/
5
About Tetratherix
Tetratherix is an Australian medical technology company pioneering advanced biomaterial
solutions to transform how complex diseases are treated. Our proprietary polymer platform
enables the targeted delivery of cells, drugs, and biologics, unlocking new potential across
oncology, regenerative medicine and more. Tetratherix combines deep scientific innovation with
real-world clinical impact – underpinned by a novel business model designed for global
scalability and embedded collaboration with partners and healthcare systems around the world.
Overview of Tetratherix’s current product portfolio
TetramatrixTM
is the Company’s current core platform technology. This platform technology is
safe and clinically modular and therefore used to co-develop multiple products in partnership
with leading medical companies. The overarching aim to use TetramatrixTM
platform technology
in developing multiple products is to treat patients faster, cheaper, and safer. The current
portfolio of products under development with TetramatrixTM
spans several large near-term
commercial opportunities that are grouped into three franchises:
• Bone regeneration: relates to the utility of TetramatrixTM
platform’s technology to develop
products to support bone repair in dental and orthopaedic applications.
• Tissue spacing: relates to the utility of TetramatrixTM
platform technology to develop
products to generate space between two tissues or organs either to support surgical access
for ophthalmic applications or to reduce side effects to surrounding tissue and organs
during cancer treatment; and
• Tissue healing: relates to the utility of TetramatrixTM
platform technology to develop
product for use during any open surgical intervention to reduce scar formation at the
incision site.
Table 1. Three distinct markets that address unmet needs in five separate medical indications.
See more at www.tetratherix.com
6
Forward-looking statements
This announcement may contain forward-looking statements which may be identified by words
such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may”, and other
similar words that involves risks and uncertainties. Such statements are not guarantees of future
performance and involve known and unknown risks, uncertainties, assumptions and other
important factors, many of which are beyond the control of Tetratherix or its Directors and
management and could cause Tetratherix’s actual results and circumstances to differ materially
from the results and circumstances expressed or anticipated in these statements. The Directors
cannot and do not give any assurances that the results, performance, or achievements expressed
or implied by the forward-looking statements contained in this announcement will actually occur
and investors are cautioned not to place undue reliance on these forward-looking statements.
7
Appendix 1
In accordance with ASX Listing Rule 4.7C Tetratherix provides the following use of funds (UOF)
information:
REF Comment
1-4 R&D costs include specific projects, directly attributable staff, research and
laboratory costs, trademarks, patent filing, and upkeep. Specific breakdown by
project as follows
1 Bone Regeneration: activity focused on preparation for FDA clearance for Tegenix
and TegenEOS, with spending front weighted in FY26
2 Tissue Healing: ongoing clinical trial and pipeline development for TetraDerm
3 Tissue Spacing: No significant expenditure. Tutelix is funded by the joint venture.
4 Precision Medicine: No significant expenditure
5 Manufacturing expansion: a new lease was signed in August 2025. Capital
expenditure investment has commenced to commission our advanced
manufacturing facility .
6 Listed company costs: Reflects board remuneration, audit fees, share registry,
directors’ and officers’ insurance and company secretary services
7 IPO costs: All invoices have now been paid; in line with prospectus assumptions.
8 Working capital: Includes staff (ex R&D), interest, and general operating expenses
9 UOF proceeds of $33.2m includes $8.2m existing cash on hand as at 30/4 as per
prospectus plus $25 million capital raise funding.
$24.8m Closing cash balance as at 30 September 2025.
• May 2025- Sep 2025 cumulative cash outflows total ($8.0) million including ($4.1)
million for Q1 FY26
$3.3 million from the Industry Growth Program (IGP) grant, with payments
expected across FY26 and FY27 is an upside to the Company’s UOF and is not
included in the appendix 1 table. The co-funding will enable further investment in
additional R&D programs and advanced manufacturing. In Q1 FY26, $0.3 million has
been received for IGP per contract milestones
USE OF FUNDS
Prospectus
A$m
May-Sep 25
Actual
Accumulated
as %
prospectus Ref
Research and Development Bone Regeneration 2.4 1.1 47% 1
Research and Development Tissue Healing 5.3 0.7 13% 2
Research and Development Tissue Spacing 2.3 0.0 1% 3
Research and Development Precision Medicine 1.3 0.1 10% 4
Manufacturing expansion 10.2 1.7 16% 5
Listed company costs and directors fees 2.5 0.6 25% 6
Costs of the offer ($0.4m expensed YTD Apr 25) 3.4 3.4 100% 7
Working capital 5.8 1.2 20% 8
Total Cash outflows 33.2 8.8 26% 9
8
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Tetratherix Limited
ABN Quarter ended (“current quarter”)
72 607 771 077 30 September 2025
Consolidated statement of cash flows Current quarter
$A’000
Year to date (3
months) $A’000
1. Cash flows from operating activities
3 3
1.1 Receipts from customers
1.2 Payments for
(977) (977)
(a) research and development
(b) product manufacturing and operating costs 0 0
(c) advertising and marketing (68) (68)
(d) leased assets (23) (23)
(e) staff costs (1,399) (1,399)
(f) administration and corporate costs (714) (714)
1.3 Dividends received (see note 3) 0 0
1.4 Interest received 205 205
1.5 Interest and other costs of finance paid 0 0
1.6 Income taxes paid 0 0
1.7 Government grants and tax incentives 393 393
1.8 Other (provide details if material)
1.9 Net cash from / (used in) operating activities (2,580) (2,580)
2. Cash flows from investing activities
0 0
2.1 Payments to acquire or for:
(a) entities
(b) businesses 0 0
(c) property, plant and equipment (786) (786)
(d) investments (820) (820)
(e) intellectual property
(f) other non-current assets
0
0
0
0
2.2 Proceeds from disposal of:
0 0
(a) entities
(b) businesses 0 0
9
Consolidated statement of cash flows Current quarter
$A’000
Year to date (3
months) $A’000
(c) property, plant and equipment 0 0
(d) investments 0 0
(e) intellectual property 0 0
(f) other non-current assets 0 0
2.3 Cash flows from loans to other entities 0 0
2.4 Dividends received (see note 3) 0 0
2.5 Other (provide details if material) 0 0
2.6 Net cash from / (used in) investing activities (1,607) (1,607)
3. Cash flows from financing activities
0 0
3.1 Proceeds from issues of equity securities
(excluding convertible debt securities)
3.2 Proceeds from issue of convertible debt
securities
0 0
3.3 Proceeds from exercise of options 0 0
3.4 Transaction costs related to issues of equity
securities or convertible debt securities
(357) (357)
3.5 Proceeds from borrowings 0 0
3.6 Repayment of borrowings 0 0
3.7 Transaction costs related to loans and
borrowings
0 0
3.8 Dividends paid 0 0
3.9 Other (provide details if material) 0 0
3.10 Net cash from / (used in) financing activities (357) (357)
4. Net increase / (decrease) in cash and cash
equivalents for the period
29,336 29,336
4.1 Cash and cash equivalents at beginning of
period
4.2 Net cash from / (used in) operating activities
(item 1.9 above)
(2,580) (2,580)
4.3 Net cash from / (used in) investing activities
(item 2.6 above)
(1,607) (1,607)
4.4 Net cash from / (used in) financing activities
(item 3.10 above)
(325) (325)
4.5 Effect of movement in exchange rates on cash
held
4.6 Cash and cash equivalents at end of period 24,791 24,791
10
5. Reconciliation of cash and cash equivalents
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
Current quarter
$A’000
Previous quarter
$A’000
5.1 Bank balances 12,728 12,728
5.2 Call deposits 12,063 12,063
5.3 Bank overdrafts 0 0
5.4 Other (provide details) 0 0
5.5 Cash and cash equivalents at end of quarter
(should equal item 4.6 above)
24,791 24,791
6. Payments to related parties of the entity and their associates Current quarter
$A'000
6.1 Aggregate amount of payments to related parties and their associates
included in item 1
780
6.2 Aggregate amount of payments to related parties and their associates
included in item 2
0
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of,
and an explanation for, such payments.
6.1 Note: Payments to related parties include executive and non-executive directors’ salaries, super, and listing
incentive bonus; and directors’ fees and listing incentive bonus paid to entities associated with directors.
7. Financing facilities
Note: the term “facility’ includes all forms of
financing arrangements available to the entity.
Add notes as necessary for an understanding of
the sources of finance available to the entity.
Total facility amount
at quarter end
$A’000
Amount drawn at
quarter end
$A’000
7.1 Loan facilities 0 0
7.2 Credit standby arrangements 0 0
7.3 Other (please specify) 0 0
7.4 Total financing facilities 0 0
7.5 Unused financing facilities available at quarter end 0
7.6 Include in the box below a description of each facility above, including the lender, interest rate,
maturity date and whether it is secured or unsecured. If any additional financing facilities have been
entered into or are proposed to be entered into after quarter end, include a note providing details of
those facilities as well.
Not applicable
11
8. Estimated cash available for future operating activities $A’000
8.1 Net cash from / (used in) operating activities (item 1.9) (2,580)
8.2 Cash and cash equivalents at quarter end (item 4.6) 24,791
8.3 Unused finance facilities available at quarter end (item 7.5) 0
8.4 Total available funding (item 8.2 + item 8.3) 22,211
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1) 8.6
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a figure for the
estimated quarters of funding available must be included in item 8.5.
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash
flows for the time being and, if not, why not?
Answer: N/A
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to
fund its operations and, if so, what are those steps and how likely does it believe that they will
be successful?
Answer: N/A
8.6.3 Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: N/A
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
12
Compliance statement
1 This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2 This statement gives a true and fair view of the matters disclosed.
Date: 27 October 2025
Authorised by: By the Board
(Name of body or officer authorising release – see note 4)
Notes
1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has
been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing
activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: “By the
board”. If it has been authorised for release to the market by a committee of your board of directors, you can insert
here: “By the [name of board committee – e.g. Audit and Risk Committee]”. If it has been authorised for release to the
market by a disclosure committee, you can insert here: “By the Disclosure Committee”.
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out
as complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles
and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the
financial records of the entity have been properly maintained, that this report complies with the appropriate accounting
standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the
basis of a sound system of risk management and internal control which is operating effectively.
Share your feedback
Discover